Compare Roundhill Magnificent Seven ETF (MAGS) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill Magnificent Seven ETF vs Novavax Inc — how do they compare? Roundhill Magnificent Seven ETF trades at $67.74, while Novavax Inc trades at $7.94 (market cap $1.31B). The key difference: Roundhill Magnificent Seven ETF is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| MAGS | NVAX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $70.94 | $11.19 |
52-Week Low | $55.39 | $6.22 |
Market Cap | — | $1.31B |
Enterprise Value | — | $889.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MAGS (Roundhill Magnificent Seven ETF) trades at $67.685, down 1.96% with technical indicators showing bullish moving averages but overbought RSI levels. The ETF faces headwinds as AI spending pressures tech balance sheets, with recent underperformance against the broader market. News sentiment highlights a shift away from concentrated tech exposure toward diversified sectors.
The outlook remains cautious as AI capital expenditures weigh on near-term returns, though long-term AI adoption potential persists. Key risks include tech concentration, valuation compression, and earnings growth sustainability. Investors should monitor broadening market trends and hyperscaler cash flow improvements for catalyst opportunities.
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
